Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents

about

Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents

Item

http://www.wikidata.org/entity/Q37495788

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents

@en

Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents.

@nl

type

Item

label

Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents

@en

Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents.

@nl

prefLabel

Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents

@en

Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents.

@nl

P1476

Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents

@en

P2093

Abhishek Maan

http://www.w3.org/2001/XMLSchema#string

E Kevin Heist

http://www.w3.org/2001/XMLSchema#string

Jeremy N Ruskin

http://www.w3.org/2001/XMLSchema#string

Moussa Mansour

http://www.w3.org/2001/XMLSchema#string

P2860

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran versus warfarin in patients with atrial fibrillation

The ecarin clotting time, a universal method to quantify direct thrombin inhibitors

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Thrombin signalling and protease-activated receptors

Apixaban metabolism and pharmacokinetics after oral administration to humans.

Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents.

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

P304

825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4022/JAFIB.825

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28496855

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

P932

5153064

http://www.w3.org/2001/XMLSchema#string